Edit
Moleculera Labs, Inc.
http://www.moleculera.com/Last activity: 03.02.2026
Active - Reference to Moleculera Labs
Moleculera Labs is developing advanced testing services that help physicians decide whether a child’s neurologic symptoms could be caused by autoimmune dysfunction resulting from common infections.
Visit The Website
Visit The Website
Total raised: $1.84M
Investors 1
| Date | Name | Website |
| - | Prolog Ven... | prologvent... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 03.10.2013 | - | $1.84M | - |
Mentions in press and media 9
| Date | Title | Description |
| 03.02.2026 | Moleculera Biosciences Achieves CAP Accreditation, Demonstrating Diagnostic Testing Excellence | Accreditation reflects the company’s adherence to the highest standards of laboratory quality, stewardship, and clinical performance. Achieving CAP accreditation validates the discipline and quality in our laboratory processes.” — Craig Shi... |
| 01.10.2025 | Moleculera Biosciences advances first-of-its-kind biomarker panel for Alzheimer’s through alliance with Lunai Bioworks | Leveraging biomarkers, personal history measures and advanced AI platform to develop test that detects Alzheimer’s disease prior to symptom onset and diagnosis Our vision is to shift the paradigm of Alzheimer’s detection upstream — giving p... |
| 16.04.2025 | Moleculera Biosciences Appoints Dr. Michael Rossbach to its Advisory Board as International Commercial Strategy Advisor | Michael Rossbach, PhD, International Commercial Strategy Advisor Newly appointed advisor to assist in the company’s international expansion and growth Moleculera's international reach is growing, having medical provider requests from over 5... |
| 20.03.2025 | Moleculera Biosciences names Rod Whitson as Strategic Advisor for Growth and Implementation | Rod Whitson, Strategic Advisor for Growth and Implementation Moleculera, a precision medicine company, expands Advisory Board as it enters a new phase of accelerated growth, market expansion and operational scaling. Rod's ability to transla... |
| 22.08.2024 | Moleculera Biosciences Names B. Robert Mozayeni, MD as Medical and Clinical Advisor | Dr. B. Robert Mozayeni, Medical and Clinical Advisor Appointment will provide strategic guidance and insights as the company expands scope of work for immune-mediated disorders With his vast background in rheumatology, immunology and scient... |
| 30.07.2024 | Moleculera Labs announces rebrand to Moleculera Biosciences as company expands into new sectors | Rebrand aligns with precision medicine messaging for growth and expansion into additional immune-mediated disorder markets Medicine is recognizing that inflammation and immune dysfunction are underlying causes of many chronic disorders, and... |
| 23.05.2024 | Moleculera Biosciences Board of Directors names Healthcare Innovator and Leader Dr. Vijay Aggarwal as Board Chair | Vijay Aggarwal, PhD Moleculera Biosciences Board Chair Dr. Aggarwal's vast life sciences industry experience will help us achieve our vision to change how medicine is practiced for those suffering from immune-mediated CNS and cardiovascular... |
| 11.01.2024 | Moleculera Labs, Inc., Awarded $500,000 Grant Funding to Develop Predictive Treatment Algorithm | Company leveraging strategic alliance w/OKC-based General Genomics to build next-gen predictive treatment model for immune-mediated neuropsychiatric disorders With over 15,000 patient outcomes, we anticipate the ability to predict effective... |
| 03.10.2013 | Moleculera Labs Raises $1.84M in Funding | Moleculera Labs, Inc., an Oklahoma City-based developer of tests to predict a patient’s likelihood to have Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococci (PANDAS), raised $1.84m in funding. The round was led by ... |